Jaguar Animal Health (NASDAQ:JAGX) Raised to Sell at Wall Street Zen

Jaguar Animal Health (NASDAQ:JAGX) was upgraded by analysts at Wall Street Zen to a “sell” rating in a research note issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jaguar Animal Health in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Jaguar Animal Health Stock Performance

Jaguar Animal Health stock opened at $4.79 on Friday. Jaguar Animal Health has a 52 week low of $2.35 and a 52 week high of $1,260.00. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.40 and a current ratio of 0.69. The firm has a market capitalization of $1.63 million, a PE ratio of -0.00 and a beta of -0.11. The business’s 50-day simple moving average is $9.58 and its 200-day simple moving average is $59.20.

Jaguar Animal Health (NASDAQ:JAGX) last issued its quarterly earnings results on Wednesday, August 19th. The biotechnology company reported ($15.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($782.25) by $766.55. The company had revenue of $1.23 million during the quarter, compared to the consensus estimate of $4.24 million.

About Jaguar Animal Health

Jaguar Animal Health, Inc is a commercial-stage animal health company focused on developing and marketing products for gastrointestinal disorders in companion and production animals. Its research is centered on plant-based medicines, including products derived from the red-barked croton tree, Croton lechleri, traditionally used in South America.

The company’s lead animal health product is Canalevia-CA1, a prescription drug containing crofelemer that received conditional approval from the U.S.